Revenue

12 Months Ended

Sep. 30, 2023

Revenue from Contract with Customer [Abstract]

Revenue

3. Revenue

The following is a disaggregation of revenue within each reportable segment:

	Fiscal Year
(In thousands)	2023		2022		2021
Medical Device
Product sales	$	34,126	$	27,930	$	21,777
Royalties & license fees – performance coatings		32,812		30,547		31,007
License fees – SurVeil DCB		29,586		5,701		16,049
Research, development and other		9,259		8,211		9,420
Medical Device revenue		105,783		72,389		78,253
In Vitro Diagnostics
Product sales		26,488		26,691		24,701
Research, development and other		313		871		2,182
In Vitro Diagnostics revenue		26,801		27,562		26,883
Total Revenue	$	132,584	$	99,951	$	105,136

Contract assets totaled $7.8 million and $7.1 million as of September 30, 2023 and 2022, respectively, on the consolidated balance sheets. Fluctuations in the balance of contract assets result primarily from changes in sales-based and minimum royalties earned, but not collected at each balance sheet date due to payment timing and contractual changes in the normal course of business. For discussion of contract liability (deferred revenue) balances and remaining performance obligations, see Note 4 Collaborative Arrangement.

Revenue from customers that equaled or exceeded 10% of total revenue was as follows:

	Fiscal Year
	2023			2022			2021
Abbott		27	%		11	%		21	%
Medtronic		10	%		13	%		13	%

Revenue by geographic region was as follows:

	Fiscal Year
	2023			2022			2021
Domestic		82	%		74	%		79	%
Foreign		18	%		26	%		21	%